JAK/TYK2
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent…
New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a…
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR…
2 years ago
Opportunistic Infections with JAK inhibitors in RA
Winthrop and colleagues have reviewed the occurrence of OIs associated with the use of JAK inhibitors in patients with RA, showing that Herpez zoster (HZ) was the most common OI reported.
https://t.co/CtFcnHiWKS https://t.co/qKU51vLxaP
Poster Hall